Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Azilsartan

Maiah D. Hardin, Preeti Patel, Tibb F. Jacobs  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Azilsartan

Maiah D. Hardin et al.
Free Books & Documents

Excerpt

Azilsartan is an angiotensin II receptor blocker used in the management of hypertension to reduce cardiovascular risk and protect against end-organ damage. By selectively inhibiting angiotensin II binding to the angiotensin II type 1 receptor, azilsartan causes vasodilation, reduces aldosterone secretion, and lowers blood pressure without significantly affecting heart rate. This activity explores the pharmacological properties of azilsartan, including its mechanism of action, pharmacokinetics, clinical indications, contraindications, and potential adverse effects. The course also reviews considerations for administration, off-label uses, and drug interactions that may influence therapeutic response. Understanding the pharmacology and safety profile of azilsartan enables healthcare professionals to select appropriate patients, tailor therapy to individual needs, and improve outcomes in the management of hypertension.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Maiah Hardin declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Tibb Jacobs declares no relevant financial relationships with ineligible companies.

References

    1. Katsi V, Michalakeas C, Soulaidopoulos S, Antonopoulos AS, Vlachopoulos C, Tousoulis D, Tsioufis K. Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review. Curr Hypertens Rev. 2021;17(3):217-227. - PubMed
    1. Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. - PMC - PubMed
    1. Zhu L, Wei GC, Xiao Q, Chen QL, Zhao Q, Li XX, Pan LA, Xiong X. Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1383217. - PMC - PubMed
    1. Wang JG, Zhang M, Feng YQ, Ma CS, Wang TD, Zhu ZM, Kario K. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich) 2021 May;23(5):901-914. - PMC - PubMed
    1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. - PubMed

Publication types

LinkOut - more resources